IDH1 and central nervous system cancer: The ability to discriminate the IDH1 mutation in glioma TMA sections with 80% accuracy would likely be clinically acceptable, although future studies should also consider probing fresh tissue biopsies rather than FFPE tissue microarrays, which would be better suited to the determination of a patient’s IDH1 status mid-surgery.